Why Chicago Is an Underused Advantage for Diverse Trial Enrollment

The Chicago metropolitan area is the third-largest market in the United States, with more than 9.5 million residents and a demographic composition — roughly a third White, 30% Hispanic/Latino, and 29% Black/African American — that is unusually well-suited to the enrollment diversity requirements sponsors now face under FDA guidance.

Diverse enrollment is not simply a compliance checkbox. Disease burden in the Chicago metro area, including higher-than-average rates of diabetes, obesity, chronic pain, and depression, means the population most affected by many of the conditions our therapeutic areas address is also the population most represented in our recruitment funnel.

Meaningful diverse enrollment requires more than proximity to a diverse population — it requires trust, language access, and logistical support that removes real barriers to participation. Our recruitment approach combines database marketing from an opt-in research registry, community partnerships with health centers and civic organizations, and multilingual coordinators, alongside practical retention support like ride-share vouchers and flexible evening and weekend scheduling.

For sponsors under increasing pressure to demonstrate representative enrollment in FDA diversity action plans, we see this as one of the clearest, most concrete ways a site can add value beyond raw enrollment speed.